

YOUR ACTIVE INVOLVEMENT IN DRUG DEVELOPMENT

*Dear Doctor/ Oncologist,
Welcome to our 3-monthly oncology newsletter of the Phase 1 Clinical Trial Centre! Your support is important to us and we hope to keep you in touch with our early-phase oncology research activities and facilitate the referral process. Please feel free to contact us using the links below if you are interested in referring patients to any of our studies.*



Oncology early-phase studies under recruitment

Oncology focus

1. **Recurrent or metastatic Head and neck cancer (squamous):**

- **Inclusion:** Age 18 and above, ECOG 0-1, failed prior chemo-RT/ 1 line of platinum-based chemo. For details: http://www.clo.cuhk.edu.hk/cctu/trials_phase1.html (HAN008)
- **Principal Investigator:** Prof. Brigette Ma
- **Contact (for doctors only):** You are encouraged to contact us first before making a medical referral. Please email brigitte@clo.cuhk.edu.hk, or p1ctc@cuhk.edu.hk.

2. **Recurrent or metastatic esophageal cancer (squamous):**


- **Inclusion criteria:** Age 18 and above, ECOG 0-1, failed 1 line of palliative chemo, or relapse within 6 months of radical RT. For details: http://www.clo.cuhk.edu.hk/cctu/trials_phase1.html (HAN010)
- **Principal Investigator:** Prof. Brigette Ma
- **Contact (for doctors only):** You are encouraged to contact us first before making a medical referral. Please email brigitte@clo.cuhk.edu.hk, or p1ctc@cuhk.edu.hk.

3. **Recurrent or metastatic EGFR wild-type with high c-MET expression NSCLC patients:**

- **Inclusion criteria:** Age 18 and above, ECOG 0-1, patients should not receive more than three prior lines of antineoplastic therapy for NSCLC. For details: http://www.clo.cuhk.edu.hk/cctu/trials_phase1.html (ACT004)
- **Principal Investigator:** Prof. Brigette Ma
- **Contact (for doctors only):** You are encouraged to contact us first before making a medical referral. Please email brigitte@clo.cuhk.edu.hk, or p1ctc@cuhk.edu.hk.

4. **Recurrent or metastatic HER2 negative hormone +ve breast cancer, Postmenopausal women**

- **Inclusion criteria:** Age 18 and above, ECOG 0-1, patient not received more than one chemotherapy line for advanced breast cancer. Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to randomization. For details: http://www.clo.cuhk.edu.hk/cctu/trials_phase1.html (BRE028)
- **Principal Investigator:** Prof. Brigette Ma
- **Contact (for doctors only):** You are encouraged to contact us first before making a medical referral. Please email brigitte@clo.cuhk.edu.hk, or p1ctc@cuhk.edu.hk.



Prof. Anthony CHAN, Chief Director of P1CTC, CUHK

CUHK Phase 1 Clinical Trial Centre



Commissioned by the Food and Health Bureau of the HKSAR Government, CUHK has established the Phase 1 Clinical Trial Centre (P1CTC) to strengthen the clinical research and development of new drugs in Hong Kong. The new P1CTC is located at the Prince of Wales Hospital and it strengthens our capacity to early-phase clinical studies in oncology and non-oncology areas. We strive to become an internationally recognized centre of excellence for the development of new drugs.

Oncology early-phase studies

Phase 1 clinical trials have an important role for the development of novel anti-cancer drugs. Even though therapeutic effect is not the primary objective of phase 1 studies, with more new targeted therapy even to pharmacogenomic level, the clinical benefit from current phase 1 oncology trials cannot be under-estimated.



**30% OF THE 27
NEW MOLECULAR
ENTITIES
(NMEs)
APPROVED BY US
FDA IN 2013 ARE
ONCOLOGY/
HEMATOLOGY
PRODUCTS.**



....besides a hope of disease control related to the experimental agent, it has been demonstrated that patients with cancer in phase 1 trials also receive secondary benefit from their participation.....

(Italiano A, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. *Ann Onco*, 2008; 19: 787-792)

Contact Us

Phase 1 Clinical Trial Centre, CUHK

11EF, Special Block (Wing E,F)
Prince of Wales Hospital,
30-32 Ngan Shing Street,
Shatin, Hong Kong

Email: p1ctc@cuhk.edu.hk

Your feedback on how we improve our service is important to us.

We respect your privacy, if you do not wish us to send you this newsletter again, please let us know.